Form 8-K - Current report:
SEC Accession No. 0001558370-24-010107
Filing Date
2024-07-25
Accepted
2024-07-25 07:30:14
Documents
14
Period of Report
2024-07-24
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K sngx-20240724x8k.htm   iXBRL 8-K 33328
  Complete submission text file 0001558370-24-010107.txt   161118

Data Files

Seq Description Document Type Size
2 EX-101.SCH sngx-20240724.xsd EX-101.SCH 4029
3 EX-101.DEF sngx-20240724_def.xml EX-101.DEF 3494
4 EX-101.LAB sngx-20240724_lab.xml EX-101.LAB 17257
5 EX-101.PRE sngx-20240724_pre.xml EX-101.PRE 10061
17 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20240724x8k_htm.xml XML 4842
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 241139808
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)